Skip to content

FDA Orphan Drug Designation (ODD) For Cleveland BioLabs And Incuron’s Quinacrine For Hepatocellular Carcinoma

October 9, 2012

       Cleveland BioLabs and Incuron’s Quinacrine receives FDA Orphan Drug Designation (ODD) for the treatment of hepatocellular carcinoma on September 28, 2012. 

        Per Cleveland BioLabs’ October 2, 2012 Press Release :

  1. It is estimated that there are 30,000 US & 45,000 EU annual cases of hepatocellular carcinoma
  2. Overall survival rate is about 15%
  3. Quinacrine is orally administered
  4. Incuron is a “Russian Federation based joint venture founded in 2010 between Russian Closed Mutual Venture Fund ‘Bioprocess Capital Ventures’ & Cleveland BioLabs”.
Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: